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Background: TNF-α has accelerating role in development of type 1 diabetes. Although an immunosupressor
function and leading protecting role in T1DM also has been claimed for this pro-inflammatory cytokine.
Over-expression of pro-inflammatory and type 1 cytokines (Th1, like IFN-γ) drive insulitis toward the destructive form
that leads to type 1 diabetes (T1DM). Among type 1 cytokines only IFN-γ has been detectable in the islet β cells. In
deletion studies IFN-γ was also the only Th1 cytokine for which its ablation or blockade caused delayed or
decreased incidence of T1DM.
Methods: Functional polymorphisms of TNF-α at position −308*G/A and at position +874*T/A of IFN-γ gene were
employed as markers and the comparative distribution of derived genotypes/alleles were assessed in 248 British
Caucasian T1DM patients and 118 healthy controls.
Results: There was no significant association between IFN-γ gene polymorphism and T1DM or the diabetic
complication triad. There was a marginal association between TNF-α –308*G/A polymorphism in nephropaths
(vs healthy controls) (p = 0.06), which its insignificancy may be due to survivor factor. No significant association was
evident between the genotype/allele of the applied marker and T1DM or diabetic complication triad.
Conclusion: Our results are in contrast with previous reports suggesting that these polymorphisms are not related
to T1DM. This study also underlines the importance of replication of association studies to confirm the previous
interpretation.Introduction
TNF-α gene in human is a single copy gene and is lo-
cated on the short arm of chromosome 6 in close link-
age with MHC genes [1].
TNF-α is a potent inflammatory mediator, which is pro-
duced by monocytes, macrophages, CD4+ and CD8+ T
cells, B cells, lymphokine-activated killer (LAK) cells, NK
cells, endothelial cells, a number of non-haematopoietic
tumour cell lines and also other sources such as mast cells
and neutrophils upon stimulation [2,3]. General expres-
sion of TNF-α receptors by a wide variety of cells and
tissues suggests that TNF-α is involved in a number of
biological activities [4]. Besides its pro-inflammatory role,
TNF-α has other functions such as promotion of T cell* Correspondence: tavakkolybazzazj@tums.ac.ir
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reproduction in any medium, provided the orproliferation in vitro [5,6], prevention of T cell deletion in-
duced by superantigens [7], and it critically influences
germinal centre formation following immunization [8]. In
pathological circumstances, all of these properties, which
contribute to the establishment, maintenance, or accentu-
ation of specific immune responses, could aberrantly end
in tissue injury [4].
Interferon-gamma (IFN-γ), also known as type II inter-
feron or macrophage-activating factor (MAF), was ori-
ginally identified due to its antiviral activity. The mature
IFN-γ protein has a molecular weight about 17 kDa [9].
Both genetic and environmental factors contribute to
the onset of T1DM [10] and its chronic complications.
Genetic susceptibility to T1DM probably includes an
inherited defect in the establishment of peripheral toler-
ance to β cell autoantigens. One of the most important
genetic risk factors is inheritance of particular NOD
MHC class II alleles [11,12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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flammatory and autoimmune diseases has encouraged
researchers to pursue the influence of different TNF-α
gene polymorphisms on development of some diseases
including T1DM by a series of association studies. While
TNF-α has also metabolic potentials, the impact of its
polymorphisms on glucose dysmetabolism and related
consequences has not been studied yet.
TNF-α gene polymorphisms and their impacts on the
level of TNF-α production and diseases have been
reviewed [1].
It is well documented that the destructive form of insu-
litis is associated with over-expression of pro-inflammatory
(IL-1, TNF-α, and IFN-α) and type 1 cytokines (IFN-γ,
TNF-β, IL-2 and IL-12), whereas the up-regulation of type
2 (IL-4 and IL-10) and type 3 cytokines (TGF-β1) are re-
ported in benign insulitis, reflecting the role for cytokines
as regulators as well as mediators of immune responses.
Also, in deletion studies of type 1 cytokines, the protecting
effect of cytokine ablation was exclusive for IFN-γ. It has
been observed that the knocking out of the IFN-γ gene,
IFN-γ neutralisation, IFN-γ blockade, or deletion of IFN-
γ-R positive cells in NOD mice and BB rats all led to de-
layed or decreased incidence of T1DM [13].
The human IFN-γ gene is located on chromosome 12,
spaning 6 kb in length and contains four exons and
intermediate introns [14].
The IFN-γ polymorphism at position +874*T/A in the
first intron is correlated with the level of the IFN-γ pro-
duction, where allele T is the high producer. This poly-
morphism coincides with a putative NF-κB binding site
that may mediate high production of IFN-γ [15]. The
previously reported CA repeat polymorphism in the first
intron [16] of which allele 2 (12 CA repeats) was the
producer of higher level, is immediately adjacent and ab-
solutely correlated with allele T of the polymorphism at
position +874 [17].
In present study genetic susceptibility to T1DM and
its chronic complications have been monitored through
a potentially shared contributor, TNF-α and IFN-γ.
The frequency of the TNF-α gene polymorphism at
position −308*G/A, which influences the transcriptional
activation [18] and the level of its expression [19-21] be-
sides IFN-γ polymorphism at position +874*T/A was
examined in 248 Caucasian T1DM patients and 119
healthy controls.Patients and controls
In this cross-sectional study, in total 248 unrelated British
Caucasian with T1DM were randomly selected among
patients attending Manchester Diabetes Centre during
1999–2002. The ethical approval was obtained from the
Manchester Royal Infirmary.All patients fulfilled the relevant criteria for related
diagnosis as are detailed below. To be on the safe side,
patients who had diabetes less than 3 years were ex-
cluded from analysis.
Type 1 diabetes
Diabetes was diagnosed according to the criteria, which
was suggested by an expert committee in 1997 (report of
the expert committee on the diagnosis and classification
of diabetes Mellitus, 1997). The diabetic patients in-
cluded in the present study fulfilled at least one of the
triple criteria recommended by the expert committee,
detailed as follows:
a) Symptoms of hyperglycaemia (polyuria, polydipisia,
unexplained weight loss) plus random plasma
glucose > 200 mg/dL (11.1 mmol/L). Random is
defined as any time of day without regard to time
since last meal.
b) Fasting plasma glucose (FPG) > 126 mg/dl
(7.0 mmol/L). Fasting is defined as no caloric intake
for at least 8 hours.
c) 2-hour plasma glucose (PG) > 200 mg/dl (11.1 mmol/L)
during an oral glucose tolerance test (OGTT). The
test should be performed as described by the World
Health Organization (WHO), using a glucose load
containing the equivalent of 75-g anhydrous glucose
dissolved in water.
Diabetes was regarded as T1DM if it was diagnosed
before age of 30 years and accompanied with acute onset
and treatment with insulin began within the first year of
diagnosis and continued thereafter.
Diabetic retinopathy (DR)
The back of the eye was examined by fundoscopy (after
pupillary dilatation) and when more than five dots or
blots per eye, hard or soft exudates or new vessels were
evident the diagnosis of retinopathy was applied. Pa-
tients who had a history of laser treatment were also di-
agnosed as retinopathy.
Diabetic nephropathy (DN)
The elevation of AER (> 300 mg-2 g/day) at least on two
of three occasions and/or 3 positive Albustix over the past
12 months were evident to mark patients as nephropath,
while a urinary tract infection (UTI) was ruled out already.
Diabetic neuropathy (DNU)
Neurothesiometer -a clinical electromagnetic vibrating
device- was applied for screening of peripheral diabetic
neuropathy, which quantifies the vibration sensitivity
through the measurment of vibratory perception thresh-
old (VPT), while the patient’s eye is closed and the probe
Bazzaz et al. Journal of Diabetes & Metabolic Disorders 2014, 13:46 Page 3 of 7
http://www.jdmdonline.com/content/13/1/46of neurothesiometer is placed on the hallux of the toe.
An average of 3 readings were taken. DNU was diag-
nosed when VPT was more than 25 volts (vibration
threshold above 25 volts indicates a high risk of ulcer-
ation). The symptoms of sensory and/or motor neur-
opathy were looked for, like parasthesia, numbness,
tingling, nocturnal rest ache, all in the absence of per-
ipheral vascular disease as non-specific (non-diabetic)
underlying cause. The excluding of peripheral vascular
disease was approved by palpable pulses and measuring
of ankle brachial pressure index.Materials and methods
The ARMS-PCR method was applied for genotyping of
TNF-α -308*G/A polymorphism and IFN-γ +874*T/A
polymorphism. The sequences of designed primers were
illustrated in Table 1.
A master mix solution was used for DNA amplifica-
tion. This master mix includes 22% of Ready Load Reac-
tion Buffer (AB Technology, UK), 22% of 200 μM
dNTPs (AB Technology, UK), 13% of 1.5 mM magne-
sium chloride (AB Technology, UK), 31% of 60% (W/V)
sucrose, 11% internal control primer (1 μM each), and
1.1% of Thermoprime DNA Polymerase (AB Technol-
ogy, UK). For each sample, 1.5 μl of DNA was added to
15 μl of the master mix solution and then 5 μl of specific
primer mix was aliquoted to 5 μl of master mix solution,
which already contains DNA as well. After that, this
10 μl reaction was amplified on a PTC-100 PCR thermal
cycler (MJ Research, Inc), where the cycles was pro-
grammed as follows: 1 minute at 96°C followed by 10
cycles of 15 seconds at 95°C, 50 seconds at 65°C for
TNF-α and 62°C for IFN-γ 40 seconds at 72°C followed
by 20 cycles of 20 seconds at 95°C, 50 seconds at 59°C
and 50 seconds at 72°C.
In gel electrophoresis, according to the presence or ab-
sence of amplified targeted sequence, the type of alleles
(genotype) were identified. The amplified products wereTable 1 Primer sequences for TNF-α and IFN-γ gene
polymorphisms genotyping
Internal control primers (Human growth hormone)
HGH1 5′- GCCTTCCCAACCATTCCCTTA-3′ PCR product













5′-TTCTTACAACACAAAATCAAATCA-3′visualized on a 2% agarose gel against 200 bp ladders
and stained with 5 μl (0.5 mg/ml) of ethidium bromide.
Results
None of the diabetic late complications were signifi-
cantly correlated with the gender (p > 0.05). Among triad
of diabetic complications only in DR group the impact
of age at the onset > 15 years was statistically determin-
ant (p = 0.0008) for the development DR. The impact of
the age at the onset was insignificant for the develop-
ment of both DN (p = 0.2) and DNU (p = 0.7) (Figure 1).
Please insert Figure 1 (as follow).
No significant differences were evident in the distribution
of IFN-γ +874*T/A and TNF-α -308*G/A polymorphism
among cases, controls and different subgroups. Tables 2
and 3.
Discussion
TNF-α as a pro-inflammatory cytokine is crucial con-
tributor in development of T1DM, as its functional dis-
ruption by specific lack of TNF-α-R1 leads to profound
protection from autoimmune diabetes [22]. However,
during T cell mediated autoimmunity TNF-α as a Th1
cytokine exacerbates the evolvement of autoimmune dis-
eases like T1DM [23]. In contrast it can act as an immu-
nosuppressor as well. The time and site of exposure to
TNF-α determine the outcome [24]. When it is injected
in NOD mice before 4 weeks of age [25] or expressed
transgenically at β islets in neonatal NOD mice [26] it
promotes the course of autoimmune reactions and predis-
poses the animal to T1DM. On the contrary, its late,
transgenic expression leads to dampening of auto-reactive
T cell repertoire and protection from diabetes [27].
The diabetogenic impact of TNF-α in transgenic
NOD mice is ascribed to the early recruitment and acti-
vation of Dendritic cells and macrophages and, then by
reinforcement of self-antigen uptake and presentation
and not via the direct effect on β cells [26]. While
immuno-suppressory role of TNF-α may be attributable
to its promoting effect on T cell apoptosis in turning off
unnecessary immune responses [28] or attenuating its
impact on TCR signal transduction pathways due to
chronic stimulation with TNF-α [29].
Due to possessing of another range of functions (other
than pro-inflammatory) mainly suppression of insulin
signalling, TNF-α can be regarded yet again as a candi-
date in aethiopathogenesis of diabetic late complications.
However, this dual functionality of TNF-α in backward-
looking analysis (such as the present cross sectional
study) cannot be distinguished from each other as any
association between TNF-α genotype and late complica-
tions may be secondary to a primary association between
TNF-α and T1DM itself. But the diabetic subjects who






1 2 3 4 5 6 7 8
Age at the onset > 15
(N) 66 85 69 77 76 74
Age at the onset < 15
(N) 34 15 31 23 24 26
%
Figure 1 Microvascular diabetic complications according to the age at the onset of diabetes (under or over 15 years).
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cation that could minimize the bias tic impact of previ-
ous association.
The polymorphism of TNF-α gene at position −308*G/A
is reportedly correlated with transcriptional activation [18]
and its functionality has been described. While some re-
ports claimed allele A is the higher producer variant
[18,20], in contrary allele G also was found as the high
producer [19,21] as well.
Since our data did not demonstrate any significant as-
sociation between TNF-α–308*G/A polymorphic geno-
types/alleles with T1DM or its complications, however
there was a consistent increase in frequency of allele A
among patients at each category relative to healthy con-
trols. In respect to controversial findings mentioned
above such increased frequency of allele A in type 1 dia-
betics as a whole can be interpreted in two ways. Either
the allele A is the high producer or the low producer
variant, and because TNF-α can play a dual role, both
promoter and dampener in development of T1DM. But
with reference to the steady increased frequency of alleleTable 2 Distribution of genotype and allele frequencies of th
type 1 diabetic subjects (P), diabetic retinopaths (DR), nephro
group*
IFN-γ +874*T/A C n (%) P n (%) DR
Genotype
TT 26 (22.0) 54 (22.0) 27
TA 62 (52.0) 128 (51.0) 70
AA 31 (26.0) 66 (27.0) 38
Allele
T 114 (48.0) 236 (47.6) 124
A 124 (52.0) 260 (52.4) 146
*There were no significant differences between controls and diabetic patients or beA throughout other categories (different complications)
where the elevated level of TNF-α might be favored in
their development, in overall these may confer that allele
A is possibly the high producer variant (at least in the
case of diabetic context).
The greatest difference in distribution of polymorphic
alleles was evident in the diabetic nephropath subgroup,
where the significance was marginal (p = 0.06). The dis-
tinctiveness of the nephropath subgroup can be explained
by a stronger role of TNF-α in development of DN relative
to two other complications. It may also be due to more in-
fluential capacity of genetic issues in development of DN
rather than DR and DNU.
Furthermore, since DN is the only complication among
the three complications which is followed by mortal out-
come, the previous removal of a fraction of nephropaths
by death, who should had carried the risky genotypes
more frequently than the survivor nephropaths may have
biased the present results. If all patients with nephropathy
were taken into account, i.e. by prospective (follow-up)
study, the marginal difference possibly will reach thee IFN-γ +874*T/A polymorphism in healthy controls (C),
paths (DN), neuropaths (DNU) and complication free (CF)
n (%) DN n (%) DNU n (%) CF n (%)
(20.0) 18 (21.0) 17 (21.0) 23 (23.5)
(52.0) 45 (52.0) 43 (52.0) 49 (50.0)
(28.0) 23 (27.0) 22 (27.0) 26 (26.5)
(46.0) 81 (47.0) 77 (47.0) 95 (48.5)
(54.0) 91 (53.0) 87 (53.0) 101 (51.5)
tween patients with or without diabetic complications.
Table 3 Distribution of genotype and allele frequencies of the TNF-α at −308*G/A polymorphism in healthy controls
(C), T1DM subjects (P), diabetic retinopaths (DR), nephropaths (DN), neuropaths (DNU) and complication free (CF)
group*
TNF-α −308*G/A C n (%) P n (%) DR n (%) DN n (%) DNU n (%) CF n (%)
Genotype
GG 73 (62.0) 136 (54.8) 75 (55.5) 44 (51.2) 46 (56.1) 54 (55.1)
GA 39 (33.0) 91 (36.7) 49 (36.3) 33 (38.4) 29 (35.4) 36 (36.7)
AA 6 (5.0) 21 (8.5) 11 (8.2) 9 (10.5) 7 (8.5) 8 (8.2)
Allele
G 185 (78.4) 363 (73.2) 199 (73.7) 121 (70.4) 121 (73.8) 144 (73.5)
A 51 (21.6) 133 (26.8) 71 (26.3) 51 (29.6) 43 (26.2) 52 (26.5)
*No significance difference was evident between any groups/subgroups.
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study should be repeated in independent group of patients
reminding that the appropriateness of our interpretation
in case–control studies basically depends on reproducibil-
ity of the results in different group of patients.
The distribution of the polymorphic alleles also was
compared between diabetic nephropaths and diabetic
subjects without DN and the difference was not signifi-
cant. Likewise there was no significant difference in fre-
quency of those alleles neither between diabetic subjects
with and without DR and those with and without DNU.
The frequency of allele A in diabetics who were free
from the triad of late complications was similar to other
subgroups (except DN) and to diabetics as a whole. Such
sameness in allele frequency may firstly criticize the sound-
ness of patients’ stratification in complication free group,
as they were placed in a group by the “lack” of too broad
manifestations (different complications). Otherwise, it may
imply that in terms of diabetic complications this poly-
morphism is not reliable/capable to partition the diabetic
subjects, while it may do so in combination with other
polymorphic markers (in the same or nearby genes) and by
adding the number and power of detecting mechanism.
While the non-significant role of TNF-α gene poly-
morphism in development of T1DM in the present
study is consistent with the result of another study, con-
ducted in US Caucasian and Chinese diabetics living in
Taiwan [30], following points can be raised as conclud-
ing remarks.
Although TNF-α may have opposing accelerating/
protecting effects in development of T1DM; we antici-
pated a linkage between TNF-α and T1DM and with its
late complications. However, association studies can give
false results. Small numbers of cases/controls, lack of
homogeneity in cases/controls population, uncertainty in
clinical definitions and inexactness in patients’ selection,
selection of the wrong SNP (other SNP rather than −308)
and other inconsistencies may contribute to false negative
results. For instance while the present study has 90%
power to detect an association with an odds ratio (OR) of3 or more, the sample size is clearly underpowered to de-
tect an association with an OR less than 2, which may be
the anticipated level of association in multigenic complex
traits. On the other hand, a multivariate trait like diabetic
complications can be produced or be influenced by differ-
ent proportional contribution of genetic vs environmental
factors. For example, in order to reduce the number of
variables we can categorize the patients’ group according
to the duration of diabetes at the onset of each complica-
tion that eliminates the impact of such a major environ-
mental factor and places patients in phenotypically more
homogeneous sub-groups, which in turn requires a higher
number of patients to reach statistical power.
IFN-γ seems to be extremely important in susceptibility
and progression of diabetes. In this study there was also
no significant association between IFN-γ gene polymorph-
ism at position +874*T/A and diabetes or its chronic
microvascular complications The lack of association be-
tween the +874*T allele and diabetes may suggest that this
polymorphism is not functional in the context of diabetes.
Other polymorphisms may be of importance in β cell
destruction.
The main intent to select IFN-γ as a candidate was to
explore its effect in the development of diabetes rather
than its complications. Although the selected poly-
morphism had advantageous criteria (functionality, high
frequency of both alleles), the number of patients was
reasonably high and well-defined diagnostic criteria were
employed to characterize patients, it seems that the like-
lihood to interpret our findings as a false negative result
due to a methodological problem is low. However, in
two independent studies associations of IFN-γ poly-
morphisms with T1DM have been reported. One poly-
morphism was the CA repeat polymorphism located
within the first intron [31] and the other in the promoter
region at position −590*C/T [32]. The high producer allele
of CA repeat polymorphism is the same as the +874*T
allele genotyped in this study. The inconsistency of associ-
ation may be due either to differences in the location of
the examined polymorphism (−590 compared with +874),
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irregularity (presence/absence) of linkage disequilibrium
between the examined allele and the causative allele in
close proximity among different subjects (population ad-
mixture). It is obvious that if the examined polymorphism
was the very allele linked to diabetes, it should demon-
strate constant association in all instances, even in strati-
fied populations.
Similar to other cytokines, IFN-γ may retard or accel-
erate the course of T1DM development, according to
the dose, frequency, site and timing of its administration,
and also the species of diabetes-prone animal model
(NOD mouse or BB rat). For example, while the local
expression of IFN-γ has a tolerance breaking and diabe-
togenic effect in Balb/C mice, in NOD mice this expres-
sion has a protective effect. IFN-γ, in addition to
selective inhibitory effects on Th2 cells proliferation, has
an intricate role in antiviral host defense mechanisms
and enhancement of inflammatory reactions.
The pro-inflammatory role of IFN-γ in exacerbation of
autoimmune responses can be considered at different
levels. One of the main mechanisms is up-regulation of
MHC expression on both professional APCs [33] and
the cells under attack [34]. IFN-γ can also influence the
processing and presentation of self-antigens in target or-
gans by macrophages and DCs [35].
The exact mechanisms for an anti-inflammatory role
of IFN-γ are not clearly pointed out. IFN-γ can either
directly [36] or indirectly (via triggering of Bcl2-
mediated apoptosis) [37] suppress autoreactive T cells.
It also has been reported that the cell death of activated
autoreactive T cell is induced by anti-TCR mAbs (as
mimic ligands) in the absence of co-stimulatory cells
which has been proposed as the third mechanism of tol-
erance besides intra-thymic deletion of developing auto-
reactive T cells and peripheral inactivation of mature,
naïve T cells [38].
The lack of association is not surprising for diabetic
complications, where IFN-γ cannot be considered as a
pivotal mediator. But with regard to the crucial role of
IFN-γ in the development of diabetes these findings may
highlight the bi-directional (pro/anti) impact of IFN-γ in
the development of T1DM. While the dynamic actions
of IFN-γ (namely in time and site-dependent manner) in
terms of T1DM anticipates different outcomes, it seems
such complexity (relativity) may not be deciphered by
the association test which examines the absolute role of
a given polymorphism in a very large phenotypic entity
(disease).
Repeating this study collecting higher number of
samples and polymorphisms covering entire length of
the gene the power of the study will be increased. Div-
iding patients into groups according to their clinical
data, namely the duration of diabetes at the time ofcomplication onset, and the severity of each complica-
tion, makes them more homogeneous and reduces the
number of confounding factors bringing the light into
the role of genetic factors in disease modification.
Conclusion
The irreproducibility of results in association studies in
a disease may reflect its stochastic nature. It worth draw-
ing attention to the fact that just 6 of 166 positive asso-
ciations that have been reassessed three or more times
have been able to reproduce same results. It is concern-
ing also that among over 600 reported positive associa-
tions, over 400 of those have not yet been replicated
more than twice and still are on the waiting list for fur-
ther evaluation [39].
However, despite the acknowledged limitations of as-
sociation studies, they have been particularly recom-
mended in genetic dissection of complex traits [40],
regardless of the fact that they can only give suggestive
clues rather than absolute proof.
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